Genomically humanized animals obtained by the introduction of entire human genomic loci into model organisms are invaluable tools as disease models, for investigating cis-acting regulatory elements, and understanding their role in domainwide regulation, as well as for several biomedical applications ([@r1]). The development of humanized animal models has been mainly limited to mice via transgenic and embryonic stem (ES) cell-based technologies ([@r2]). Since rats are widely used animal models for studying human disease and for testing the efficacy and toxicity of drugs, their humanization would be more preferable over that of mice for various applications ([@r3], [@r4]). However, since complex manipulation in rat ES cells is much more challenging, megabase (Mb)-sized humanized rat models have yet to be developed, possibly owing to the chromosomal instability during long in vitro culture ([@r5]).

The generation of humanized mouse models with Mb-sized human genomic loci is very difficult via conventional gene transfer techniques, including the use of plasmids, P1-derived artificial chromosomes (PACs), and bacterial artificial chromosomes (BACs), due to the capacity for cloning DNA ([@r6][@r7]--[@r8]). To overcome this obstacle, sequential recombinase-mediated cassette exchange (S-RMCE) or sequential knockin via BACs in mouse ES cells was used to develop humanized mice with Mb-sized large genomic DNA ([@r9], [@r10]). However, these methods are very laborious owing to the requirement for more than five rounds of cloning, selection of correctly targeted mouse ES cell clones, and testing their capacity to form chimeric mice at each step.

This challenge was addressed by applying transchromosomic (Tc) technology using human chromosome fragments (hCFs), or human artificial chromosomes (HACs), to generate mice with Mb-sized segments of the human genome ([@r11][@r12][@r13][@r14][@r15][@r16]--[@r17]). The most significant problem with freely segregating chromosomes with human centromeres has been mosaicism, possibly owing to the instability of hCFs or HACs in mice. Thus, to improve the stability, we constructed mouse artificial chromosome (MAC) vectors from a native mouse chromosome by chromosome engineering ([@r18]). The MAC vector was more stable in adult tissues and hematopoietic cells in mice than hCFs or HAC vectors ([@r18], [@r19]). However, the cloning of large Mb-sized segments from human chromosomes into MACs and the application of Tc technology with hCFs/HACs/MACs to rats have not been reported.

Since the Tc technology can introduce a Mb-sized human gene but not disrupt the orthologous gene, the Tc technologies are required to combine with knockout (KO) technologies such as conventional KO technologies in mouse ES cells or genome editing to generate fully humanized animal models. Genome editing technologies, such as zinc-finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), and clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9), were utilized to induce mutations or large genomic deletions for orthologous gene cluster KO animals ([@r20][@r21][@r22][@r23]--[@r24]).

In the present study, we established a strategy for the development of Mb-sized gene cluster humanized rat models by combining MAC-mediated genomic transfer (MMGT) and genome editing technologies. As a proof of concept, we targeted the UDP glucuronosyltransferase family 2 (UGT2) gene cluster and the cytochrome P450 family 3 subfamily A (CYP3A) gene cluster because of their important roles in drug metabolism and the reported species differences in these genes between humans and rodents ([@r25], [@r26]). Although the UDP glucuronosyltransferase family 1 (UGT1) has a very important role in drug metabolism ([@r27]), we decided to select the comparably important UGT2 cluster for humanization because of its significantly larger size (∼1.5 Mb versus ∼200 kb), allowing for more challenging validation of the technology. We established stable humanized Tc rat lines harboring a ∼1.5-Mb region including the *UGT2* cluster (10 coding genes) from human chromosome 4 (hChr.4) or a ∼700-kb region including the *CYP3A* cluster (four coding genes) from hChr.7 by the transfer of MACs with desired gene clusters. Furthermore, we disrupted the endogenous rat *Ugt2* gene cluster (∼762 kb) or rat *Cyp3a* (*Cyp3a23/1* and *Cyp3a2*) using genome editing technologies. We also confirmed the retention of the MAC, and the expected tissue-specific expression and enzymatic function of the UGT2 and CYP3A enzymes in rats.

Results {#s1}
=======

Construction of UGT2-MAC and CYP3A-MAC. {#s2}
---------------------------------------

A MAC vector stably maintained in mice has been developed and various small- to intermediate-size genes of interest from circular vectors such as plasmids, PACs, and BACs have been transferred to the MAC vector by a site-specific recombination system for several applications ([@r28][@r29]--[@r30]). However, the loading of a large Mb-sized gene cluster to the MAC vectors has not been demonstrated yet. In this study, the HAC-mediated Mb-sized gene cloning system developed previously was thus applied to the MAC vector and the MMGT was applied to rat ([@r31], [@r32]). To generate "humanized" Tc rats with the entire human *UGT2* cluster (10 coding genes: *UGT2B4*, *UGT2B7*, *UGT2B10*, *UGT2B11*, *UGT2B15*, *UGT2B17*, *UGT2B28*, *UGT2A1*, *UGT2A2*, and *UGT2A3*) or CYP3A cluster (4 coding genes: *CYP3A4*, *CYP3A5*, *CYP3A7*, and *CYP3A43*), two MACs containing these clusters were constructed using the Cre/loxP-mediated Mb-sized gene cloning system ([Fig. 1](#fig01){ref-type="fig"}).

![Construction of UGT2-MAC and production of fully humanized UGT2 rats. A schematic diagram of UGT2-MAC construction and fully humanized UGT2 rat production. hChr.4 was transferred from A9 cells to DT40 cells via MMCT and modified in DT40 cells. Telomere-associated chromosomal truncation was carried out at the telomere side of the UGT2 cluster and loxP insertion was conducted at its centromere side in DT40 cells. Modified hChr.4 was transferred to CHO cells containing the MAC vector via MMCT. Cre/loxP-mediated reciprocal translocation generated the UGT2-MAC and a by-product. The UGT2-MAC was transferred to rat ES cells and chimeric Tc rats were produced. Tc rat lines generated through germline transmission were further mated with KO rats generated by genome editing to produce fully humanized UGT2 rats.](pnas.1808255116fig01){#fig01}

To clone ∼1.5 Mb of the *UGT2* cluster on hChr.4 into a MAC (MAC4), hChr.4 was transferred from mouse A9 cells to homologous recombination-proficient DT40 cells using microcell-mediated chromosome transfer (MMCT). The hChr.4 was truncated at the AC125239 locus and a loxP sequence was introduced into the AC074378 locus on the hChr.4 in DT40 cells ([Fig. 2*A*](#fig02){ref-type="fig"} and [*SI Appendix*, Figs. S1--S3](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808255116/-/DCSupplemental)). The modified hChr.4, hChr.4-∆AC125239-loxP in DT40 cells was then introduced into Chinese hamster ovary (CHO) cells containing one of the MAC vectors (MAC4 with hygromycin resistant gene, EGFP gene, and loxP) using MMCT to obtain hybrid CHO clones with two different exogenous chromosomes: the MAC4 and the modified hChr.4 (hChr.4-∆AC125239-loxP). To induce reciprocal translocation between the MAC4 and the modified hChr.4, Cre expression vectors were transfected into the CHO hybrids, and recombinant clones were selected. Two out of six drug-resistant clones were PCR positive with *UGT2* cluster-, MAC-, and HPRT-reconstitution-specific primers ([*SI Appendix*, Fig. S4](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808255116/-/DCSupplemental)). Fluorescence in situ hybridization (FISH) analyses showed that the defined region of hChr.4 containing the *UGT2* cluster had been cloned into the MAC4 vector in the CHO hybrid cells (designated UGT2-MAC) ([Fig. 2*A*](#fig02){ref-type="fig"}). The CYP3A-MAC was also constructed as described above for the UGT2-MAC ([Fig. 2*B*](#fig02){ref-type="fig"} and [*SI Appendix*, Figs. S5--S7](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808255116/-/DCSupplemental)).

![Construction of UGT2-MAC and CYP3A-MAC, and production of Tc rats carrying UGT2-MAC or CYP3A-MAC. (*A*) Process of UGT2-MAC construction. hChr.4 was truncated at the AC125239 locus and loxP was inserted at the AC074378 locus. The UGT2 cluster was cloned into the MAC4 via a Cre/loxP-mediated reciprocal translocation cloning system. *Lower* shows FISH images before and after translocation cloning in CHO cells. *Left* shows CHO cells containing the modified hChr.4 and the MAC4. *Right* shows CHO cells containing the UGT2-MAC and by-product. The arrowhead indicates the UGT2-MAC. (*B*) Process of CYP3A-MAC construction. hChr.7 was truncated at the AC073842 locus and a loxP site was inserted at the AC004922 locus. The CYP3A cluster was cloned into the MAC1 as described for the UGT2-MAC construction. *Lower* shows FISH images before and after translocation cloning in CHO cells. *Left* shows CHO cells containing the modified hChr.7 and the MAC1. *Right* shows CHO cells containing the CYP3A-MAC and by-product. The arrowhead indicates the CYP3A-MAC. (*C*) FISH image of rat ES cell containing the UGT2-MAC. The arrow shows the UGT2-MAC and the *Inset* presents an enlarged image of it. (*D*) Chimeric rats obtained via injection of rat ES cells carrying the UGT2-MAC. (*E*) Karyotype of Tc rat containing the UGT2-MAC. (*F*) FISH image of rat ES cell containing the CYP3A-MAC. The arrow shows the CYP3A-MAC and the *Inset* presents an enlarged image of it. (*G*) Chimeric rats obtained via injection of rat ES cells carrying the CYP3A-MAC. (*H*) Karyotype of Tc rat containing the CYP3A-MAC.](pnas.1808255116fig02){#fig02}

Generation of Tc Mice with CYP3A-MAC. {#s3}
-------------------------------------

Before the generation of Tc rats with the MACs, the MAC function was tested in mice because no MAC with a Mb-sized gene or gene cluster had ever been transferred in mice. Tc mice with the CYP3A-MAC and fully humanized CYP3A (CYP3A-MAC/Cyp3a-KO) mice were generated. FISH, flow cytometry (FCM), reverse transcription-PCR (RT-PCR), and drug-metabolizing activity analyses showed that the CYP3A-MAC was functional and more stably maintained than CYP3A-HAC in mice, and that the CYP3A-MAC has the same stability as the empty MAC ([*SI Appendix*, Figs. S8--S11](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808255116/-/DCSupplemental)) ([@r16], [@r18]).

Generation of Tc Rats with UGT2-MAC or CYP3A-MAC. {#s4}
-------------------------------------------------

Establishment of germline-competent rat ES cells with the MAC-carrying gene cluster is challenging due to chromosome instability of rat ES cells during long-term culture. The UGT2-MAC and CYP3A-MAC were introduced into a male rat ES cell line (BLK2i-1) via CHO cells using MMCT. PCR analyses using primers for the detection of the UGT2-MAC or CYP3A-MAC showed that 12 of 22 BLK2i-1 (UGT2-MAC) clones and 11 of 12 BLK2i-1 (CYP3A-MAC) clones contained intact UGT2-MAC and CYP3A-MAC, respectively. FISH analyses showed that the UGT2-MAC and the CYP3A-MAC were present as an individual chromosome without integration into the host rat chromosomes in BLK2i-1 (UGT2-MAC) and BLK2i-1 (CYP3A-MAC) clones, respectively ([Fig. 2 *C* and *F*](#fig02){ref-type="fig"}). Two BLK2i-1 (UGT2-MAC) clones and 4 BLK2i-1 (CYP3A-MAC) clones that were karyotypically normal were used for the subsequent production of chimeras.

In the case of UTG2-MAC rat chimera production, among 13 male chimeric rats, 2 (15%) were capable of germline transmission ([Fig. 2*D*](#fig02){ref-type="fig"} and [Table 1](#t01){ref-type="table"}). FISH analyses showed that a single UGT2-MAC was contained in the Tc rat ([Fig. 2*E*](#fig02){ref-type="fig"}). In the case of CYP3A-MAC rat chimera production, among 31 male chimeric rats, 11 (35%) were capable of germline transmission ([Fig. 2*G*](#fig02){ref-type="fig"} and [Table 1](#t01){ref-type="table"}). FISH analyses showed that a single CYP3A-MAC was contained in the Tc rat ([Fig. 2*H*](#fig02){ref-type="fig"}). Taken together, the MACs with gene cluster were successfully transferred to germline-competent rat ES cells and transmitted through the germline. The germline-transmitted Tc UGT2-MAC rats and Tc CYP3A-MAC rats were mated with the Ugt2-KO rats and Cyp3a-KO rats, respectively, to generate humanized rats, as described below. Both humanized UGT2 and CYP3A rats transmitted the UGT2-MAC and CYP3A-MAC, respectively, stably at least beyond the F~8~ generation.

###### 

Production of chimeric Tc rat and germline-transmitted Tc rat

  Gene    Line no.   No. of injected embryos   No. of embryos developed to pups (%)   No. of pups analyzed   No. of chimeras (%)   GT chimeras/total male chimeras
  ------- ---------- ------------------------- -------------------------------------- ---------------------- --------------------- ---------------------------------
  UGT2    1          33                        13 (39)                                13                     10 (77)               2/8
          2          60                        36 (60)                                35                     19 (54)               0/5
  CYP3A   4          35                        11 (31)                                11                     9 (82)                4/7
          8          60                        21 (35)                                21                     18 (86)               4/8
          11         70                        46 (66)                                46                     30 (65)               2/9
          21         36                        22 (61)                                22                     21 (95)               1/7

GT, germline transmission.

Generation of Ugt2-KO and Cyp3a-KO Rats. {#s5}
----------------------------------------

### Ugt2 cluster KO. {#s6}

The simultaneous formation of two double-strand breaks (DSBs) causes the joining of separate breakage sites, resulting in loss of the region between the two DSB sites. Only *Ugt2* genes are included in the rat *Ugt2* cluster, which allowed us to apply the large deletion approach for the generation of Ugt2 KO rats. To produce *Ugt2* cluster (∼762-kb) KO rats, we simultaneously induced two targeted DSBs in the rat genome using the CRISPR/Cas9 system. hCas9 mRNA and two gRNAs with target sites upstream of *Ugt2a1* and the coding region of Ugt2b31-like were injected into rat fertilized eggs ([Fig. 3*A*](#fig03){ref-type="fig"}). Finally, we obtained one *Ugt2* cluster KO rat strain with concatenation of the genomic sequence upstream of *Ugt2a1*, a 102-bp insertion, and the *Ugt2b31-like* region. To confirm the disruption of rat UGT2 function, gemfibrozil glucuronidation activity, a typical marker activity of UGT2 enzymes, was then investigated in the F~2~ rats with homozygous deletion ([@r33]). The gemfibrozil glucuronidation activity test revealed the decrease of metabolic activity in the liver of Ugt2-KO rats compared with that of wild-type (WT) rats ([Fig. 3*B*](#fig03){ref-type="fig"}). These results suggested the functional deletion of rat *Ugt2* genes in the Ugt2-KO rats. The Ugt2 cluster KO rats were mated with the Tc UGT2-MAC rats to generate fully humanized UGT2 rats (designated UGT2-MAC/Ugt2-KO rats). The Ugt2-KO and UGT2-MAC/Ugt2-KO rats did not display any obvious physiological abnormalities. They grew up without any significant abnormalities, especially in terms of body weight, and showed no anatomical differences compared with the WT controls.

![Production of Ugt2 cluster KO, and Cyp3a23/3a1 and Cyp3a2 KO rats, and enzyme activities in their liver microsomes. (*A*) Schematic view of the rat Ugt2 cluster genomic region and the CRISPR/Cas9-induced large deletion. Blue and red represent the target sequences of each gRNA. Protospacer adjacent motif (PAM) sequences are highlighted in green. The junction sequence after deletion of the Ugt2 cluster is shown at the *Bottom*. (*B*) Gemfibrozil was time-dependently incubated with liver microsomes prepared from WT and Ugt2-KO rats. The concentration of gemfibrozil glucuronide is shown. (*C*) Schematic view of the rat Cyp3a23/3a1 and Cyp3a2 genomic region and sites of gene disruption by TALEN. Exon/intron structures are shown. *Left* and *Right* TALEN target sequences are highlighted in red and blue, respectively. Mismatches are shown in green. (*D*) Results of 4-OH triazolam activity for each strain (*n* = 2). Liver microsomes were incubated with 200 µM triazolam for 30 min. Formation of 4-OH triazolam was determined using HPLC. Data are the mean of duplicate assays.](pnas.1808255116fig03){#fig03}

### Cyp3a-KO. {#s7}

Among rat Cyp3as, Cyp3a23/3a1 and Cyp3a2 are the major CYP3A enzymes in the liver ([@r34], [@r35]). In addition, these enzymes can metabolize some prototypical substrates of human CYP3A enzymes ([@r36], [@r37]). Thus, in this study, we decided to disrupt the most important Cyp3a genes, *3a23/3a1* and *3a2*, via TALEN. A pair of TALEN mRNAs targeting exon 5 of rat *Cyp3a23/3a1* and *Cyp3a2* were injected into rat fertilized eggs ([Fig. 3*C*](#fig03){ref-type="fig"} and [*SI Appendix*, Fig. S12](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808255116/-/DCSupplemental)). Finally, we produced two independent homozygous big deletion (BD) mutants (derived from nos. 32 and 58) and four independent homozygous insertion/deletion mutants including the 3-bp insertion (derived from no. 51), the 1-bp deletion (derived from no. 62), the 9-bp deletion, and the 30-bp deletion (each derived from no. 65). To confirm the disruption of rat CYP3A function, the metabolic activity of triazolam, a typical marker of the activity of CYP3A enzymes ([@r38]), was then investigated in the six homozygous rat lines. Triazolam metabolic activity testing revealed the loss of CYP3A activity compared with that of WT rats and humans in five out of the six lines, but not in one line (no. 62) ([Fig. 3*D*](#fig03){ref-type="fig"}). We randomly selected two lines, no. 65 with the 9-bp deletion (designated \#65del9) and no. 58 with a BD mutation (designated \#58) for further investigation. As with rat Cyp3a2 BD for \#65del9 and \#58 ([*SI Appendix*, Fig. S12*B*](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808255116/-/DCSupplemental)), rat Cyp3a was considered to be functionally deleted in both lines by disruption of *Cyp3a23/3a1* and *Cyp3a2* via TALEN (Cyp3a-KO). Thus, the \#58- and \#65del9-Cyp3a-KO rat strains were selected for the production of humanized CYP3A rats. The Cyp3a-KO rats were mated with the Tc CYP3A-MAC rats to generate CYP3A-humanized rats (designated CYP3A-MAC/Cyp3a-KO rats). As in the Ugt2-KO and UGT2-MAC/Ugt2-KO rats, the resultant Cyp3a-KO and CYP3A-MAC/Cyp3a-KO rats also did not display any obvious physiological or anatomical abnormalities.

Characterization of UGT2- and CYP3A-Humanized Rats. {#s8}
---------------------------------------------------

EGFP encoded by the UGT2-MAC/CYP3A-MAC was expressed in all tissues examined, suggesting that the UGT2-MAC/CYP3A-MAC was retained in the respective organs ([Fig. 4 *A* and *E*](#fig04){ref-type="fig"}). FISH analyses showed that the UGT2-MAC and CYP3A-MAC was detected in ≥84% and ≥90% of cells, respectively, in all examined tissues, including the liver, intestine, kidney, spleen, lung, heart, muscle, thymus, brain, and testis ([Fig. 4 *B*, *C*, *F*, and *G*](#fig04){ref-type="fig"}). To confirm expression of the genes from the UGT2-MAC/CYP3A-MAC, RT-PCR analyses were conducted on various tissues from the Tc rat. In the UGT2-MAC/Ugt2-KO rats, *UGT2A3* was expressed in the liver, small intestine, and kidney; *UGT2B4* was mainly expressed in the liver; *UGT2B7* was expressed in the liver, small intestine, kidney, and lung; *UGT2B10* was expressed in the liver; *UGT2B11* was mainly expressed in the liver, small intestine, and kidney; *UGT2B15* was mainly expressed in the liver, small intestine, lung, brain, and testis; and *UGT2B28* was mainly expressed in the liver, small intestine, and kidney ([Fig. 4*D*](#fig04){ref-type="fig"}). These expression profiles are largely consistent with those observed in humans ([@r39]). To confirm the effect of UGT2 KO and humanization on the expression of the related endogenous Ugt1 drug-metabolizing enzymes, we determined the relative expression levels of rat *Ugt1a1*, *Ugt1a5*, and *Ugt1a8* in the liver of WT, Ugt2-KO, and UGT2-MAC/Ugt2-KO rats. We selected those genes because a previous report showed that their hepatic expression levels in WT rats were remarkably high compared with those in other tissues ([@r40]). According to our results, there was no significant difference in the hepatic expression levels of these genes among the three different rat lines ([*SI Appendix*, Fig. S13](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808255116/-/DCSupplemental)). Therefore, Ugt2 KO and humanization do not significantly affect the expression of the endogenous rat Ugt1 genes that we analyzed in this study.

![Analyses of UGT2-MAC and CYP3A-MAC retention, and gene expression profiles in humanized UGT2 and CYP3A rats. (*A*) GFP images of different tissues from Tc rat carrying the UGT2-MAC. GFP expression indicates the presence of the MAC. (*B*) Representative FISH image of liver cells from Tc rat with the UGT2-MAC. The arrowhead shows the UGT2-MAC. Red and green indicate the MAC and UGT2 cluster, respectively. (*C*) Retention rate of the UGT2-MAC in various Tc rat tissues analyzed by FISH. (*D*) RT-PCR analyses for UGT2 gene expression in different Tc rat tissues. (*E*) GFP images of different tissues from Tc rat carrying the CYP3A-MAC. GFP expression indicates the presence of the MAC. (*F*) Representative FISH image of liver cells from Tc rat with the CYP3A-MAC. The arrowhead shows the CYP3A-MAC. Red and green indicate the MAC and CYP3A cluster, respectively. (*G*) Retention rate of the CYP3A-MAC in various Tc rat tissues analyzed by FISH. (*H*) RT-PCR analyses for human CYP3A4 and CYP3A5 expression in different Tc rat tissues.](pnas.1808255116fig04){#fig04}

In the CYP3A-MAC/Cyp3a-KO rats, both *CYP3A4* and *CYP3A5* were robustly expressed in the liver and small intestine, and *CYP3A5* additionally in the lung ([Fig. 4*H*](#fig04){ref-type="fig"}). This expression profile is consistent with the one observed in the previously generated humanized CYP3A-HAC mice and in humans ([@r16], [@r41], [@r42]). To confirm the effect of Cyp3a KO and humanization on the expression of other major Cyp enzymes in rat livers ([@r43]), we determined the relative expression levels of rat *Cyp1a2*, *Cyp2c11*, and *Cyp2d2* in the liver of WT, Cyp3a-KO, and CYP3A-MAC/Cyp3a-KO rats ([*SI Appendix*, Fig. S14](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808255116/-/DCSupplemental)). Cyp3a KO moderately increased the rat *Cyp1a2* expression level, while the expression level in CYP3A-MAC/Cyp3a-KO rats was similar to that in WT rats. The expression levels of rat *Cyp2c11* were highly increased in both Cyp3a-KO and CYP3A-MAC/Cyp3a-KO rats at a similar level. The rat *Cyp2d2* expression was moderately increased in both Cyp3a-KO and CYP3A-MAC/Cyp3a-KO rats. Thus, Cyp3a KO may affect the expression of other endogenous rat Cyp enzymes. On the other hand, since the hydroxylation activities of triazolam were much lower in the liver of Cyp3a-KO rats ([Fig. 3*D*](#fig03){ref-type="fig"}), Cyp enzymes increased by Cyp3a KO do not affect the metabolism of triazolam in the following functional study in CYP3A-humanized rats.

Functional Analyses in UGT2- and CYP3A-Humanized Rats. {#s9}
------------------------------------------------------

### UGT2-humanized rats. {#s10}

To analyze the function of human UGT2 in rats, zidovudine and gemfibrozil glucuronidation was investigated in WT, Ugt2-KO, and UGT2-MAC/Ugt2-KO rats. In the present study, these two medications were selected as UGT2-selective substrates. Zidovudine is mainly metabolized by human UGT2B7, which is an important isoform in UGT2 family ([@r44]). In the Ugt2-KO rats, no zidovudine glucuronidation activity was observed in the liver microsomes, indicating that rat Ugt2 is not functional in the liver. In contrast, higher zidovudine glucuronidation activity was observed in an incubation time-dependent manner in the liver microsomes that were prepared from UGT2-MAC/Ugt2-KO rats as well as those from WT rats and human ([Fig. 5*A*](#fig05){ref-type="fig"}), showing that the introduced human *UGT2* gene(s) produced functional UGT2 protein(s) in the liver. These results were also confirmed using gemfibrozil as UGT2-selective substrates ([*SI Appendix*, Fig. S15](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808255116/-/DCSupplemental)). Taken together, glucuronidation activities of UGT2 substrates in liver microsomes from UGT2-MAC/Ugt2-KO rats were similar to those in human liver microsomes.

![Functional analyses of UGT2 and CYP3A in the liver of UGT2- and CYP3A-humanized rats. (*A*) Time-dependent change in the concentration of zidovudine glucuronide in the liver microsomes of WT rats, Ugt2-KO rats, UGT2-MAC/Ugt2-KO rats (*n* = 3 for each group), and humans. (*B*) Ratios of intrinsic clearance (V~max~/K~m~) for α-OH triazolam (TRZ) and 4-OH TRZ formation in liver microsomes from WT rats (gray column), CYP3A-MAC/Cyp3a-KO rats (closed column), and humans (open column). Liver microsomes were prepared from PCN-treated WT and CYP3A-MAC/Cyp3a-KO rats. Kinetic parameters (V~max~ and K~m~) were determined as described in [*Materials and Methods*](#s13){ref-type="sec"}. (*C*) Ratio of AUC for α-OH TRZ/TRZ and 4-OH TRZ/TRZ in vehicle-treated WT, vehicle-Cyp3a-KO, and PCN-treated CYP3A-MAC/Cyp3a-KO rats. (*D*) Ratio of AUC for α-OH TRZ/4-OH TRZ in vehicle-treated WT and PCN-treated CYP3A-MAC/Cyp3a-KO rats. Rats (*n* = 3 for each group) were i.v. administered triazolam (2.5 mg/kg) through the tail vein. Data are derived from [*SI Appendix*, Table S3](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808255116/-/DCSupplemental).](pnas.1808255116fig05){#fig05}

### CYP3A-humanized rats. {#s11}

To confirm the functional activity of CYP3A expressed in liver and intestine of CYP3A-MAC/Cyp3a-KO rats, the metabolites of the CYP3A probe substrate triazolam, α-OH triazolam and 4-OH triazolam, were examined ([@r45]). Treatment with pregnenolone 16α-carbonitrile (PCN), a CYP3A inducer, substantially increased the formation of α-OH triazolam and 4-OH triazolam in the liver and intestine of CYP3A-MAC/Cyp3a-KO rats, but not in Cyp3a-KO rats ([*SI Appendix*, Fig. S16](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808255116/-/DCSupplemental)). Furthermore, immunoinhibition assays showed that the anti-human CYP3A4 antibody inhibited triazolam metabolism in the liver microsomes from CYP3A-MAC/Cyp3a-KO rats but not in those from WT rats ([*SI Appendix*, Fig. S17](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808255116/-/DCSupplemental)). These findings suggest that human CYP3A proteins expressed in the liver and intestine of CYP3A-MAC/Cyp3a-KO rats were functional, and that CYP3A-specific metabolic activities in the liver and intestine of CYP3A-MAC/Cyp3a-KO rats were mediated by human CYP3A proteins expressed in the CYP3A-MAC/Cyp3a-KO rats.

The kinetics of triazolam metabolism were analyzed to assess whether the enzymatic properties of CYP3A introduced in the CYP3A-MAC/Cyp3a-KO rats were the same as those in humans ([*SI Appendix*, Fig. S18](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808255116/-/DCSupplemental)). The ratios of intrinsic clearance (V~max~/K~m~) for α-OH triazolam and 4-OH triazolam formation in the liver microsomes from CYP3A-MAC/Cyp3a-KO rats and humans were more than 20-fold higher than those from WT rats ([Fig. 5*B*](#fig05){ref-type="fig"} and [*SI Appendix*, Table S2](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808255116/-/DCSupplemental)), suggesting that the kinetics of triazolam in the liver microsomes from CYP3A-MAC/Cyp3a-KO rats were very similar to those from humans, but not to those from WT rats. Next, we analyzed the pharmacokinetic profiles of triazolam and its metabolites after its i.v. administration of triazolam ([*SI Appendix*, Figs. S19 and S20 and Table S3](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808255116/-/DCSupplemental)). The ratios of areas under the curves (AUCs) for α-OH triazolam and triazolam (α-OH/triazolam) in CYP3A-MAC/Cyp3a-KO rats were eightfold higher than those in Cyp3a-KO rats, while the AUC ratios of α-OH triazolam and 4-OH triazolam (α-OH/4-OH) in CYP3A-MAC/Cyp3a-KO rats were much higher than those in WT rats ([Fig. 5 *C* and *D*](#fig05){ref-type="fig"} and [*SI Appendix*, Table S3](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808255116/-/DCSupplemental)). After the i.v. administration of triazolam, CYP3A-MAC/Cyp3a-KO rats showed the predominant formation of α-OH triazolam, consistent with the results in liver microsomes. Similar results were also obtained after the oral administration of triazolam ([*SI Appendix*, Table S4](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808255116/-/DCSupplemental)). This observation is consistent with the clinical data in humans as described previously ([@r46]) and it reflects a clear species difference in the formation of α-OH triazolam and 4-OH triazolam between rats and humans, where the CYP3A-MAC/Cyp3a-KO rats more faithfully reflect the human situation than WT rats. Among the pharmacokinetic parameters calculated, clearances after i.v. and oral administration in Cyp3a-KO rats were lower than those in WT rats. Oral bioavailabilities in all strains were decreased by PCN treatment ([*SI Appendix*, Table S5](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808255116/-/DCSupplemental)).

To further validate the value of the CYP3A-MAC/Cyp3a-KO rats for predicting human drug metabolism, we used midazolam, another common CYP3A probe drug. As shown in [*SI Appendix*, Fig. S21](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808255116/-/DCSupplemental), midazolam was preferentially metabolized to 4-OH midazolam in liver microsomes of WT rats. In contrast, 1′-OH midazolam was preferentially formed in liver microsomes of CYP3A-MAC/Cyp3a-KO rats and humans. In summary, our results show that CYP3A-MAC/Cyp3a-KO rats reflected the human metabolism of midazolam as well as triazolam. Taken together, these results strongly support the utility of CYP3A-MAC/Cyp3a-KO rats as a model to predict human drug metabolism.

Discussion {#s12}
==========

In this study, we established a sophisticated strategy for the development of Mb-sized gene cluster humanized rat models by the approach of combining MMGT and genome editing technologies. We successfully cloned human Mb-sized gene clusters into MACs by a combination of telomere-directed chromosome truncation and loxP insertion in DT40 cells and Cre/loxP-mediated reciprocal translocation cloning in CHO cells. We subsequently introduced the MACs with Mb-sized human gene clusters into germline-competent rat ES cells. We demonstrated that MACs containing Mb-sized human gene clusters can be faithfully transmitted through the germline and maintained stably in rat tissues. Although the human *CYP3A* cluster had been previously cloned into HAC, the CYP3A-HAC was not mitotically stable in proliferative mouse tissues, such as spleen and bone marrow ([@r16]). In contrast, the CYP3A-MAC developed in this study were mitotically stable not only in mouse but also in rat tissues including organs with rapidly proliferating cells. Previously, we showed that MACs were also stably maintained in human cell lines in vitro during long-term culture ([@r19]). Thus, MACs may be useful as common vectors for the generation of larger humanized animals such as pigs, cattle, and monkeys.

To the best of our knowledge, the maximal reported size of deletion in fertilized eggs via genome editing in rat for which germline transmission can still occur was 121.7 kb ([@r47]). In this study, we succeeded in generating a Ugt2 cluster KO rat line with a ∼762-kb deletion. Previous endeavors to delete entire gene clusters mainly relied on labor- and time-intensive approaches using the Cre/loxP system, involving the targeting of two independent loxP sites at each end of the cluster, followed by Cre-mediated chromosomal deletion in ES cells and testing the capability of the ES cells to transmit the germline to the next generation at each step. Although such complex manipulations have been performed in mice, they are very difficult in rats owing to the chromosomal instability of rat ES cells. Therefore, the success of the large deletion in fertilized rat eggs described in this study is an important achievement and a prerequisite for the generation of fully humanized rats.

Rats are widely used for in vivo pharmacokinetic and drug--drug interaction studies for various reasons ([@r48]). Although rats are often considered as more advantageous models than mice for pharmacological study, the absence of complex genetic manipulation technologies in rat ES cells has thus far hindered the efficient generation of valuable humanized model rats. At least, the generation of Cyp-KO rats by genome editing have previously been described ([@r49], [@r50]). By combining the MAC approach with state-of-the-art genome engineering technologies, namely, TALEN and CRISPR/Cas9, the present study provides the successful generation of humanized UGT2 and CYP3A rats.

In this study, the tissue-specific expression pattern of *UGT2* and *CYP3A* genes observed in humans was reproduced in the humanized UGT2 and CYP3A rats. It should be noted that tissue-specific expression of *UGT2* and *CYP3A* genes has also been reported in the human prostate ([@r41], [@r51]). The analysis of the expression of UGT2 and CYP3A in prostate and their association with cancer development using the humanized UGT2 and CYP3A rats will be an interesting subject for future investigations ([@r52][@r53]--[@r54]).

The conventional Tg methods using plasmids or BACs can be associated with altered gene expression due to position effects at the site of integration into the host genome and varying copy numbers of the transgenes, making faithful reproduction of human gene expression by this approach in different species very challenging. Since the MAC technology overcomes these limitations and a single MAC containing the genes of interest can be transferred readily to different species, the MAC approach has potential to provide a very powerful tool for achieving reproducible human gene expression in a variety of different species.

The analysis of species differences is an important application for rat models humanized for drug-metabolizing enzymes, such as those described in our study. Such species differences between humans and rats have been described for hepatic glucuronidation of gemfibrozil ([@r55]). Consistent with the previous finding, the glucuronidation rate of gemfibrozil was much lower in human than in rat liver microsomes ([*SI Appendix*, Fig. S15](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808255116/-/DCSupplemental)). Notably, our humanized UGT2 rats also showed a lower rate of gemfibrozil glucuronidation than the wild-type rats ([*SI Appendix*, Fig. S15](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808255116/-/DCSupplemental)), indicating that humanized rats can mimic human glucuronidation of this compound. It has also been reported that the rates of zidovudine glucuronidation are very similar between human and rat liver microsomes ([@r56], [@r57]) and the rates of zidovudine glucuronidation were also similar in liver microsomes prepared from our humanized UGT2 rats, wild-type rats, and human in our study ([Fig. 5*A*](#fig05){ref-type="fig"}). It therefore appears likely that the described humanized UGT rats are a useful tool to predict human drug glucuronidation.

In the present functional analyses of Cyp3a-KO and humanized CYP3A rats, we used triazolam as a probe drug. Triazolam is a highly specific CYP3A substrate and its clearance occurs almost entirely by hepatic metabolism by CYP3A after i.v. administration ([@r58]). First, in vitro studies showed that the formation rates of 4-OH triazolam in the liver microsomes of Cyp3a-KO rats were lower than those of WT rats ([*SI Appendix*, Fig. S16](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808255116/-/DCSupplemental)). The in vitro findings were consistent with the in vivo findings that plasma concentrations of 4-OH triazolam in vehicle-treated Cyp3a-KO rats were lower than those in vehicle-treated WT rats ([*SI Appendix*, Fig. S19](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808255116/-/DCSupplemental)). These results suggested that triazolam was preferentially metabolized to 4-OH triazolam by rat CYP3A enzymes in WT rats. Next, in vitro studies showed low formation rates of α-OH triazolam and 4-OH triazolam in liver microsomes of vehicle-treated CYP3A-MAC/Cyp3a-KO and Cyp3a-KO rats ([*SI Appendix*, Fig. S16](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808255116/-/DCSupplemental)). Plasma concentration profiles of α-OH triazolam and 4-OH triazolam were also similar between vehicle-treated CYP3A-MAC/Cyp3a-KO and vehicle-treated Cyp3a-KO rats ([*SI Appendix*, Fig. S19](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808255116/-/DCSupplemental)), suggesting that human CYP3A-dependent formation of α-OH triazolam and 4-OH triazolam in vehicle-treated CYP3A-MAC/Cyp3a-KO rats was as low as in Cyp3a-KO rats. Importantly, however, PCN treatment increased the plasma concentrations of α-OH triazolam over those of 4-OH triazolam in CYP3A-MAC/Cyp3a-KO rats, but not in Cyp3a-KO rats. These results suggested that the human CYP3A-dependent formation of α-OH triazolam was enhanced by PCN treatment. Interestingly, plasma concentrations of 4-OH triazolam were markedly decreased and those of α,4-dihydroxytriazolam were largely increased by PCN only in WT rats ([*SI Appendix*, Figs. S19 *A* and *D* and S20](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808255116/-/DCSupplemental)), suggesting that further metabolism of 4-OH triazolam to α,4-dihydroxytriazolam may be enhanced by PCN in WT rats. The further metabolism of 4-OH complicates the comparison of the AUC ratio of α-OH triazolam and 4-OH triazolam between PCN-treated CYP3A-MAC/Cyp3a-KO and PCN-treated WT rats. Thus, the comparison of the AUC ratios in PCN-treated CYP3A-MAC/Cyp3a-KO rats with those in vehicle-treated WT rats appeared more accurate and was therefore undertaken in our analysis ([Fig. 5*D*](#fig05){ref-type="fig"}). Taking together the findings of the in vitro ([Fig. 5*B*](#fig05){ref-type="fig"}) and in vivo studies ([Fig. 5 *C* and *D*](#fig05){ref-type="fig"}), we observed that 4-OH triazolam preferentially formed in WT rats, but that α-OH triazolam was mainly formed in CYP3A-MAC/Cyp3a-KO rats and humans.

Importantly, in these so-called humanized CYP3A and UGT2 rat strains, the pharmacokinetic profiles and metabolism of relevant probe substrates observed in humans were well reproduced. In this study, we used triazolam as a probe drug to compare the performance of CYP3A enzymes in humans and rats. However, the metabolism of not only triazolam but also midazolam showed different characteristics between humans and rats ([@r59]). The preferential formation of 1′-OH midazolam rather than 4-OH midazolam occurs in human liver microsomes. In contrast, midazolam is predominantly metabolized to 4-OH midazolam in rat liver microsomes. This feature found in human liver microsomes was found in CYP3A-MAC/Cyp3a-KO rats ([*SI Appendix*, Fig. S21](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808255116/-/DCSupplemental)). Another difference between humans and rodents is the fact that CYP3A4 is expressed in human intestine and liver, whereas different CYP3A enzymes are expressed in both tissues in rodents ([@r60]). Owing to the human-like expression of CYP3A4 in liver and intestine of the described humanized rat, this model can also be applied to study differences of drug metabolism between humans and rodents resulting from the distinct tissue distribution of corresponding enzymes. Therefore, these humanized rats provide useful models not only for elucidating the mechanism of the temporal and spatial regulation of UGT2/CYP3A gene expression, but also for the improved prediction of human pharmacokinetics and drug--drug interactions.

Recently, we successfully modified the *CYP3A5* single-nucleotide polymorphism (SNP) in the humanized CYP3A mouse using genome editing technology ([@r61]). The SNP conversion of *CYP3A5* (g.6986G to A, \*3 to \*1) in the mouse ES cells and fertilized eggs recapitulated the *CYP3A5\*1* carrier phenotype in humans. This SNP conversion method can also be applied to rat ES cells or rat fertilized eggs containing MACs with human genes, such as CYP3A- and UGT2-MACs, providing a means to readily establish relevant allelic human variants from an existing MAC humanized rat model. Thus, our approaches may be applicable to understand pharmacogenetic differences between major sequences and the variants in humans.

Whereas the UGT2/CYP3A models described in the present report have primary applications in drug metabolism and pharmacokinetic studies, it should be noted that the approach described herein has compelling utility for other applications. Since MACs can carry multiple and/or very large genes, and can be transmitted through the germline and stably maintained in vivo, this technology can be used to generate rat (and presumably other animal) models containing large genomic regions of genes with known species specificities, such as genes encoding other drug-metabolizing enzymes \[*CYP2C* cluster (∼400 kb)\], drug transporters \[*OATP1* cluster (700 kb)\], or components of the immune system \[e.g., the *HLA* cluster (3 Mb), *TCRαδ* (1 Mb), *TCRβ* (620 kb), *IgH* (∼1.5 Mb), *Igκ* (∼2 Mb), and *Igλ* (∼1 Mb)\].

In summary, the described combination of chromosome transfer of Mb-sized human gene clusters via MAC and genome editing for orthologous gene disruption provides a powerful approach for the generation of fully humanized Tc rats with various important applications in basic research, drug discovery, and development.

Materials and Methods {#s13}
=====================

Cell Culture. {#s14}
-------------

UGT2-MAC and CYP3A-MAC were constructed using a previously described Mb-sized gene cloning system via HAC ([@r17], [@r31], [@r32]). MAC4 and MAC1 vectors were used to generate the UGT2-MAC and, CYP3A-MAC, respectively. The structure of MAC4 contained a centromere from mouse chromosome 11, EGFP flanked by HS4 insulators, 5′HPRT-loxP site, PGK-hyg, PGK-puro, and telomeres. The structure of MAC1 contained a centromere from mouse chromosome 11, EGFP flanked by HS4 insulators, PGK-neo, loxP-3′HPRT site, PGK-puro, and telomeres ([@r18]). Chicken DT40 cells containing hChr.4 or hChr.7 were maintained at 40 °C in RPMI medium 1640 supplemented with 10% fetal bovine serum (FBS), 1% chicken serum, 50 µM 2-mercaptoethanol, and 1.5 mg/mL G418 ([@r62]). Hprt-deficient CHO (hprt^−/−^) cells containing MAC4 or MAC1 used as fusion recipients for hChr.4 or hChr.7 transfer, respectively, were maintained at 37 °C in Ham's F-12 nutrient mixture (Invitrogen) supplemented with 10% FBS. Mouse embryonic fibroblasts (MEFs) were isolated from embryos at 13.5 day postcoitum (d.p.c.). MEFs were grown in DMEM (Sigma-Aldrich) plus 10% FBS. Parental mouse ES cell lines, TT2F, and the microcell hybrid TT2F clones were maintained on mitomycin C (Sigma-Aldrich)-treated Jcl:ICR (CLEA Japan) MEFs and neomycin-resistant MEFs (Oriental Yeast Co., Ltd.), respectively, as feeder layers in DMEM with 18% FBS (HyClone), 1 mM sodium pyruvate (Invitrogen), 0.1 mM nonessential amino acids (Invitrogen), 0.1 mM 2-mercaptoethanol (Sigma-Aldrich), 2 mM [l]{.smallcaps}-glutamine (Invitrogen), and 1,000 units/mL leukemia inhibitory factor (Funakoshi). A parental rat ES cell line (BLK2i-1, RGD ID: 10054010) and the microcell hybrid BLK2i-1 clones were maintained on mitomycin C-treated MEFs and neomycin-resistant MEFs, respectively, as feeder layers, as described previously ([@r63]).

Modification of hChr.4 and hChr.7 in DT40 Cells. {#s15}
------------------------------------------------

Homologous recombination-proficient chicken DT40 cells (1 × 10^7^) were collected in 0.5 mL of RPMI with 25 µg of linearized targeting vector and electroporated at 550 V and 25 µF using a Gene Pulser apparatus (Bio-Rad). Drug-resistant DT40 clones were selected in 1.5 mg/mL G418, 0.3 µg/mL puromycin, 1.5 mg/mL hygromycin, or 0.5 mg/mL [l]{.smallcaps}-histidinol. Homologous recombination in DT40 hybrid clones was identified by PCR analyses using primers described in [*SI Appendix*, Table S1](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1808255116/-/DCSupplemental).

MMCT. {#s16}
-----

MMCT was performed as described previously ([@r12]). DT40 cells containing the modified chromosomes (hChr.4-∆AC125239-loxP and hChr.7-loxP-∆AC073842) were transferred to CHO (MAC4) and CHO (MAC1) cells, respectively, via MMCT. To transfer the UGT2-MAC or CYP3A-MAC to mouse ES cells and rat ES cells, CHO cells containing the UGT2-MAC or CYP3A-MAC were used as donor microcell hybrids. Briefly, mouse ES and rat ES cells were fused with microcells prepared from the donor hybrid cells, and selected with G418 (250 and 150 µg/mL, respectively). The transferred UGT2-MAC and CYP3A-MAC in each line were characterized by PCR and FISH analyses.

FISH Analyses. {#s17}
--------------

The trypsinized cells and homogenized tissue samples were incubated for 15 min in 0.075 M KCl, fixed with methanol and acetic acid (3:1), and then slides were prepared using standard methods. FISH analyses were performed using fixed metaphase or interphase spreads of each cell hybrid using digoxigenin-labeled (Roche) DNA \[human COT-1 DNA/mouse COT-1 DNA (Invitrogen)\] and biotin-labeled DNA \[UGT2-BAC (RP11-643N16), CYP3A-BAC (RP11-757A13), mouse COT-1 DNA, PGK-neo, β-actin-hisD, PGK-puro, and PGK-hygro\], essentially as described previously ([@r12]). Chromosomal DNA was counterstained with DAPI (Sigma-Aldrich). Images were captured using an AxioImagerZ2 fluorescence microscope (Carl Zeiss).

Chimeric Rat Production. {#s18}
------------------------

Chimeric rats were produced as reported previously ([@r64]). Briefly, ES cells derived from each of the BLK2i-1 (UTG2-MAC) (nos. 1 and 2) and BLK2i-1 (CYP3A-MAC) (nos. 4, 8, 11, and 21) cell lines were microinjected into the blastocoel cavity of Crlj:WI E4.5 blastocysts (9--11 ES cells per blastocyst). Then, the blastocysts were transferred into uteri of pseudopregnant recipient rats at 3.5 d.p.c. (12--15 blastocysts per recipient). The contribution of the ES cells in the resultant offspring was confirmed by their coat color and/or fluorescence due to GFP gene expression. All animal experiments were approved by the Animal Care and Use Committee of National Institute for Physiological Sciences and Tottori University.
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